Bill Dahlberg
About Bill Dahlberg
Bill Dahlberg is a scientist and lab operations manager currently working at Acrivon Therapeutics and Codiak BioSciences in Cambridge, Massachusetts. He specializes in cell-based assays for oncology research and has extensive experience in various techniques related to cancer biology.
Work at Acrivon Therapeutics
Bill Dahlberg has been employed at Acrivon Therapeutics since 2020, serving as a Scientist and Lab Operations Manager. His role involves overseeing laboratory operations and contributing to scientific research efforts in Cambridge, Massachusetts. His responsibilities include managing lab workflows and ensuring that research objectives are met efficiently.
Current Role at Codiak BioSciences
In addition to his position at Acrivon Therapeutics, Bill Dahlberg has worked at Codiak BioSciences since 2018 as a Principal Associate Scientist. His work at Codiak involves advanced research in the field of biotechnology, focusing on innovative approaches to drug development in Cambridge, Massachusetts.
Previous Experience in Biotechnology
Bill Dahlberg has a background in various roles within the biotechnology sector. He served as a Principal Research Associate at FORMA Therapeutics, Inc. from 2013 to 2015, and as a Scientist at Metamark Genetics from 2010 to 2011. These positions contributed to his extensive experience in research and development within the industry.
Education and Expertise
Bill Dahlberg studied at Northeastern University, where he achieved a degree in Pharmacology. He also attended the University of Massachusetts, earning a degree in General Biology. His educational background supports his specialization in cell culture, assay development, and oncology research.
Research Specializations
Bill Dahlberg specializes in the primary culture of human normal and tumor cells derived from tissue biopsies. He has developed and optimized cell-based assays for high throughput screening of oncology compounds. His research includes drug combination studies, the use of siRNA for protein expression knock-down, and various assays to evaluate the effects of chemotherapeutic agents on different cell populations.